Skip to content

Pharmacogenomics of Anti-TNF (Anti-tumor Necrosis Factor) Treatment in Patients With Rheumatoid Arthritis

Pharmacogenomics of Anti-TNF Treatment in Patients With Rheumatoid Arthritis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00321217
Enrollment
700
Registered
2006-05-03
Start date
2004-05-31
Completion date
2014-04-30
Last updated
2012-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

rheumatoid arthritis, pharmacogenetics, anti-TNF, high throughput genotyping

Brief summary

The main aim of this study is to identify genetic markers (at DNA and RNA level) which are involved in the response to treatment with monoclonal antibodies against TNF in patients with rheumatoid arthritis.

Detailed description

Rheumatoid Arthritis (RA) is a severe inflammatory disease and genetic factors are known to play an important role in its pathogenesis. Genetic factors are also involved in determining the prognosis of RA. Identifying the genetic factors that predispose to mild or aggressive RA is not easy and up to now only a few of these factors -like certain HLA-DR species- are known. The Rheumatology department of the Radboud University Nijmegen Medical Centre (RUNMC) has collected a unique inception cohort of over 500 patients with RA, that have been followed from an early stage of disease for up to 10 years with detailed measurements of disease activity, joint damage and other characteristics of disease progression. In this project we use this patient group to study polymorphisms in a large battery of genes for their effect on RA disease activity/progression.

Interventions

None listed

Sponsors

Radboud University Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with RA according to the ACR criteria who are treated with monoclonal anti-TNF antibodies.

Countries

Netherlands

Contacts

Primary ContactM. J. Coenen, PhD
m.coenen@antrg.umcn.nl0031-24-3617649

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026